Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States

BACKGROUND: Patients with end-stage kidney disease (ESKD) on dialysis were excluded from clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised concern regarding the safety of dabigatran and rivaroxaban, but apixaban has not been evaluated despite current...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Circulation
Main Authors: Siontis, Konstantinos C., Zhang, Xiaosong, Eckard, Ashley, Bhave, Nicole, Schaubel, Douglas E., He, Kevin, Tilea, Anca, Stack, Austin G., Balkrishnan, Rajesh, Yao, Xiaoxi, Noseworthy, Peter A., Shah, Nilay D., Saran, Rajiv, Nallamothu, Brahmajee K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6202193/
https://ncbi.nlm.nih.gov/pubmed/29954737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.118.035418
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados